Management of Parkinson’s Disease Psychosis in Actual Practice (The INSYTE Study)
Sponsor:
ACADIA Pharmaceuticals Inc.
Brief Summary:
To examine the current disease progression of PDP, the clinical, economic, and humanistic
impact of anti-psychotic therapy in the management of the condition in real-world settings,
and the burden of the condition on patients and their caregivers
impact of anti-psychotic therapy in the management of the condition in real-world settings,
and the burden of the condition on patients and their caregivers
Criteria
Inclusion Criteria:
1. Adult males and females ≥ 18 with PDP
2. Ability to understand and read English
3. Patient is willing and able to sign an Informed Consent Form (ICF), or have a Legally
Authorized Representative willing and able to consent on the patient’s behalf
4. Possess the symptoms commonly associated with PDP, e.g., hallucinations and delusions
that cannot be reasonably attributed to other causes
Exclusion Criteria:
1. Patient is unwilling to participate in the non-interventional study
2. Patient is currently participating in or is planning to participate in an
investigational clinical trial
Locations
- Brain and Elective Spine Treatment Center, Laguna Hills, California, United States, 92653
- Silicon Valley Parkinson Center Inc., Los Gatos, California, United States, 95032
- Parkinson’s Disease and Movement Disorder of Silicon Valley, Menlo Park, California, United States, 94025
- Jeri Yvonne Movement Disorders Neurology, Inc., Northridge, California, United States, 91326
- Pacific Movement Disorders Center, Santa Monica, California, United States, 90404